上海赛伦生物技术股份有限公司2025年半年度报告摘要

Group 1 - The company plans to distribute a cash dividend of 1.20 RMB per 10 shares for the first half of 2025, totaling approximately 12.99 million RMB, which represents 39.38% of the net profit attributable to shareholders for the same period [2][47][48] - The company has received a total of 893.79 million RMB from its initial public offering, with a net amount of 784.92 million RMB after deducting issuance costs [4][18] - As of June 30, 2025, the company has utilized approximately 283.69 million RMB of the raised funds, leaving a balance of about 559.85 million RMB [19][21] Group 2 - The company has initiated the sales of its rabies immunoglobulin product, which has been listed on drug procurement platforms in several provinces [33][41] - The rabies immunoglobulin is designed for passive immunization against rabies and is the only product of its kind currently available for sale by the company [39][40] - The launch of the rabies immunoglobulin is expected to enhance the company's product pipeline and contribute positively to its future financial performance [41]